diagnostics
The latest news about diagnostics: headlines, AI summaries and the full story from every source.
- Revvity Reports Strong Q3 2026 Results with Raised Full-Year Guidance
- Tempus AI Projects 2026 Revenue Between $1.60B and $1.605B with Target Adjusted EBITDA of $65M
- IDEXX Laboratories Outlines 2026 Revenue and EPS Guidance
- FDA Grants 510(k) Clearance to Roche's cobas eplex Respiratory Pathogen Panel
- Abbott Announces Nutrition Business Spin-off to Focus on High-Margin Medical Technologies
- Danaher Raises 2026 EPS Guidance and Forecasts Long-Term Core Growth
- Abbott Laboratories Reports Q3 2026 Growth Driven by Diagnostics and Medical Devices
- Danaher Reports Strong Q3 2026 Results Driven by Bioprocessing and Operational Execution
- AI Reshapes Management Consulting, Shifting Value to Expertise and Execution
- Quest Diagnostics Exceeds Growth Targets as Consumer Testing Demand Rises
- IDEXX Laboratories Reaffirms Long-Term Growth Targets Amid Diagnostic Innovation
- bioAffinity Technologies Secures Patent for CyPath Lung Cancer Diagnostic in Hong Kong
- QIAGEN Launches QIAsymphony Connect Amid Strong Second-Quarter Performance
- Labcorp Outlines Growth Strategy Focused on AI and Specialty Testing Through 2029
- Qiagen Receives FDA Clearance for New Bloodstream Infection Test Panel
- Profusa Seeks to Acquire G3 Vision Labs in Potential Deal
- CareDx Announces Strong Q2 Results, Raises Full-Year Guidance
- CareDx Shares Rise on Strong Q2 Results and Raised Guidance
- Opko Health Reports Strong Q2 Earnings, Driving Over 33% Surge in Share Price
- OPKO Health Shares Drop Nearly 17% After Sharp Post-Earnings Surge
- GE HealthCare Reports Strong Q2 Earnings, Driven by Growth and Strategic Initiatives
- Abbott Raises Profit Forecast Amid Strong Performance from Diagnostics and Medical Devices
- Profusa Signs Term Sheet for Diagnostics Acquisition, Announces Leadership Changes
- Danaher Stock Slump Seen as Potential Buying Opportunity Despite Earnings Report
- Tempus Acquires Personalis for $1.5 Billion to Expand Cancer Testing Capabilities
- Abbott Raises 2026 Profit Forecast Due to Strong Performance in Diagnostics and Heart Devices
- Abbott Laboratories Reports Strong Q2 Earnings and Raises Full-Year Outlook
- En Carta Diagnostics Secures $6.18M Funding for Expansion of Molecular Testing Solutions
- Virax Biolabs Signs Supply Agreement with Fosun Diagnostics in Southeast Asia
- ALZpath's Proprietary pTau217 Antibody Featured in 86 Presentations at AAIC 2026
- Abbott Outperforms Danaher as FreeStyle Libre Drives Growth Amid Slumping Biotech Demand
- Virax Biolabs Signs Multi-Country Supply Agreement with Fosun Diagnostics
- U.S. Supreme Court Declines to Hear CareDx's Appeal Against Natera
- JPMorgan Maintains Overweight Rating on Bruker Corporation
- QuidelOrtho Said to Sell Point-of-Care Testing Unit for $1.5 Billion
- Insight Molecular Diagnostics Publishes Groundbreaking Data on GraftAssure Transplant Rejection Assay
- FDA Expands Approval of Agilent's Diagnostic Test for Keytruda Patients
- Jardine Matheson to Acquire Australian Medical Imaging Provider I-MED for $2.4 Billion
- InterVenn Appoints Alec Ford and Mitch Levine to Board of Directors
- Veracyte Stock Surges After Strong First-Quarter Earnings and Growth Outlook
- Quanterix Reports Q1 2026 Earnings with Mixed Revenue Performance
- IDEXX Laboratories Reports Strong Q1 2026 Performance with Revenue Growth and Strategic Momentum
- Bio-Rad Laboratories Reports Q1 2026 Earnings Amid Regional Challenges
- Bio-Rad Laboratories Reports Q1 Earnings Amid Middle East Conflict Impact
- Labcorp Reports Q1 2026 Earnings Results
- CareDx Acquires Naveris for $260M to Expand Precision Medicine Capabilities
- Citigroup Lowers Bio-Rad Laboratories' Price Target to $300 Due to Process Chromatography Concerns
- Danaher (DHR) Q1 2026 Earnings Call Highlights